TY - JOUR
T1 - Mind the gap
T2 - from neurons to networks to outcomes in multiple sclerosis
AU - Chard, Declan T
AU - Alahmadi, Adnan A S
AU - Audoin, Bertrand
AU - Charalambous, Thalis
AU - Enzinger, Christian
AU - Hulst, Hanneke E
AU - Rocca, Maria A
AU - Rovira, Àlex
AU - Sastre-Garriga, Jaume
AU - Schoonheim, Menno M
AU - Tijms, Betty
AU - Tur, Carmen
AU - Gandini Wheeler-Kingshott, Claudia A M
AU - Wink, Alle Meije
AU - Ciccarelli, Olga
AU - Barkhof, Frederik
AU - MAGNIMS Study Group
A2 - Frederiksen, Jette Lautrup Battistini
PY - 2021/3
Y1 - 2021/3
N2 - MRI studies have provided valuable insights into the structure and function of neural networks, particularly in health and in classical neurodegenerative conditions such as Alzheimer disease. However, such work is also highly relevant in other diseases of the CNS, including multiple sclerosis (MS). In this Review, we consider the effects of MS pathology on brain networks, as assessed using MRI, and how these changes to brain networks translate into clinical impairments. We also discuss how this knowledge can inform the targeting of MS treatments and the potential future directions for research in this area. Studying MS is challenging as its pathology involves neurodegenerative and focal inflammatory elements, both of which could disrupt neural networks. The disruption of white matter tracts in MS is reflected in changes in network efficiency, an increasingly random grey matter network topology, relative cortical disconnection, and both increases and decreases in connectivity centred around hubs such as the thalamus and the default mode network. The results of initial longitudinal studies suggest that these changes evolve rather than simply increase over time and are linked with clinical features. Studies have also identified a potential role for treatments that functionally modify neural networks as opposed to altering their structure.
AB - MRI studies have provided valuable insights into the structure and function of neural networks, particularly in health and in classical neurodegenerative conditions such as Alzheimer disease. However, such work is also highly relevant in other diseases of the CNS, including multiple sclerosis (MS). In this Review, we consider the effects of MS pathology on brain networks, as assessed using MRI, and how these changes to brain networks translate into clinical impairments. We also discuss how this knowledge can inform the targeting of MS treatments and the potential future directions for research in this area. Studying MS is challenging as its pathology involves neurodegenerative and focal inflammatory elements, both of which could disrupt neural networks. The disruption of white matter tracts in MS is reflected in changes in network efficiency, an increasingly random grey matter network topology, relative cortical disconnection, and both increases and decreases in connectivity centred around hubs such as the thalamus and the default mode network. The results of initial longitudinal studies suggest that these changes evolve rather than simply increase over time and are linked with clinical features. Studies have also identified a potential role for treatments that functionally modify neural networks as opposed to altering their structure.
KW - Alzheimer Disease/physiopathology
KW - Brain/physiopathology
KW - Humans
KW - Inflammation/physiopathology
KW - Multiple Sclerosis/physiopathology
KW - Nerve Net/physiopathology
KW - Neurons/physiology
UR - http://www.scopus.com/inward/record.url?scp=85100180908&partnerID=8YFLogxK
U2 - 10.1038/s41582-020-00439-8
DO - 10.1038/s41582-020-00439-8
M3 - Review
C2 - 33437067
VL - 17
SP - 173
EP - 184
JO - Nature Reviews Neurology
JF - Nature Reviews Neurology
SN - 1759-4758
IS - 3
ER -